html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

O-acetyl-(R)-carnitineFinding

O-acetyl-(R)-carnitine has no detected effect on LDL cholesterol

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not significantly different from that of placebo.”

Quoted verbatim from Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

This finding among the 103 findings on its endpoint

O-acetyl-(R)-carnitine

LDL cholesterol

no difference found

Who: Adults over 40 with type 2 diabetes, hypertension and dyslipidemia, all on simvastatin 10 to 20 mg/d in both arms; ALC 116 and placebo 113 randomised; 6 months
Dose studied: acetyl-L-carnitine 1000 mg orally twice daily for 6 months

Moderate evidencePMID 29696241 · 2018

02 · The study

Study: RCT
Duration: 6 months

Evidence, by strength

strong
moderatethis finding
limited
very limited
insufficient

03 · The paper

Journal of the Endocrine Society

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

2018PMID 29696241doi 10.1210/js.2017-00426

What else it reported4 findings · 1 compound · 4 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZHF7BCX7HQXHSW8NSFCZEX